Boston Scientific enters the back half of August with an unusual combination: the CEO just made a nine-figure open-market purchase, short sellers are rebuilding positions at the fastest pace in months, and a wave of analyst target cuts has left the stock trading well below where the Street thought it would be heading into summer.
The insider story is the standout this week. CEO Michael Mahoney bought 186,240 shares on August 3 at roughly $48.33, committing $9 million of his own capital. That is a material, deliberate open-market bet — not a plan-driven award or a token purchase. Director David Habiger added to his position across three separate days in early August, and Lead Independent Director Edward Ludwig bought 5,000 shares at the end of July at $45.48. Combined, net insider buying over the past 90 days totals roughly $10 million in value across 205,000 shares. The cluster of purchases — from the CEO, a lead director, and a board member — spanning a two-week window reads as coordinated conviction rather than coincidence.
The positioning picture is more mixed. Short interest has jumped sharply, nearly doubling in one week from around 20 million to 37 million shares — now representing 2.5% of the free float. That is still a low absolute level, but the pace of increase is notable: an 85% rise in seven days, following a relatively quiet stretch through mid-August. Cost to borrow has climbed alongside it, rising 54% over the week to 0.57%, though that remains modest in absolute terms. The borrow market is nowhere near stressed — availability is exceptionally loose at roughly 4,744% of short interest, meaning shares are plentiful and the new short positions are being built without friction. Options positioning leans bullish: the put/call ratio has fallen to 0.36, almost two standard deviations below its 20-day average of 0.38, the most call-heavy reading in weeks. That diverges from the short-side rebuilding — options traders are not hedging aggressively even as shorts add.
The Street's view is constructive but chastened. Eighteen analysts carry Buy or equivalent ratings versus five at Hold, giving BSX a consensus Buy. The mean price target sits near $62.69, implying roughly 26% upside from Tuesday's close at $49.86. But that number has come down hard. Following the late-July earnings print, nearly every covering analyst trimmed their target: UBS cut from $74 to $67, RBC from $85 to $70, Citi from $70 to $61, and TD Cowen from $61 to $56 — all while maintaining positive ratings. Wells Fargo held at Equal-Weight with a $50 target, essentially in line with the current price. On August 25, TD Cowen reiterated its Buy and $56 target, offering a floor of conviction. The bull case centres on AFib procedure volume growth and the potential expansion of the global AFib market toward $15 billion by 2028. Bears point to market share losses in RF and cryoablation, pricing pressure, and heavier debt. The stock is up 12.7% over the past month despite the recent pullback, and valuation has expanded: the PE multiple has moved up roughly 23% in 30 days to about 15.3x, while EV/EBITDA sits near 12.7x. The short score has crept higher this week, reaching 31.6 from 27.9 a fortnight ago — still far from extreme, but moving in one direction.
Among correlated peers, the medtech tape has been choppy. ISRG fell nearly 5% on the week and MDT dropped 1%, while ATRC bucked the trend with a 6.4% gain. BSX's own 1.2% weekly decline looks modest by comparison, though it trails the sector's brighter spots.
The next scheduled event is the Q3 earnings release on October 21. After the July print, the stock barely moved on the day — down just 0.13% — but recovered 3.6% over the following five sessions. The more important watch between now and then is whether the short-interest rebuild continues at this pace, and whether the CEO's open-market conviction at $48 proves well-timed as the stock tries to reclaim the analyst consensus range above $56.
See the live data behind this article on ORTEX.
Open BSX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
